Generic Jesduvroq Availability

Last updated on Jun 11, 2025.

Jesduvroq is a brand name of daprodustat, approved by the FDA in the following formulation(s):

JESDUVROQ (daprodustat - tablet;oral)

• Manufacturer: GLAXOSMITHKLINE
  Approval date: February 1, 2023
  Strength(s): 1MG (discontinued) ^[RLD], 2MG (discontinued) ^[RLD], 4MG (discontinued) ^[RLD], 6MG (discontinued) ^[RLD], 8MG (discontinued) ^[RLD]

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jesduvroq. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
  Patent 11,117,871
  Issued: September 14, 2021
  Inventor(s): Chen; Minhua et al.
  Assignee(s): GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (Brentford, GB)
  

  The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof. ##STR00001##

  Patent expiration dates:

  • March 13, 2038
    
    ✓ 
    Patent use: A METHOD OF TREATING ANEMIA
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Prolyl hydroxylase inhibitors
  Patent 11,643,397
  Issued: May 9, 2023
  Inventor(s): Duffy; Kevin J. et al.
  Assignee(s): GlaxoSmithKline LLC (Wilmington, DE)
  

  The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) ##STR00001##
  which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

  Patent expiration dates:

  • June 22, 2027
    
    ✓ 
    Patent use: A METHOD OF TREATING ANEMIA
    ✓ 
    Drug substance
• Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof
  Patent 11,649,217
  Issued: May 16, 2023
  Inventor(s): Chen; Minhua et al.
  Assignee(s): GlaxoSmithKline Intellectual Property (NO.2) Limited (Brentford, GB)
  

  The present disclosure relates to crystalline form CS1 and CS9 of a hypoxia-inducible factor prolyl hydroxylase inhibitor compound (I) GSK1278863, processes for preparation, and uses for preparing drugs treating and/or preventing anemia thereof. ##STR00001##

  Patent expiration dates:

  • March 13, 2038
    
    ✓ 
    Patent use: A METHOD OF TREATING ANEMIA
    ✓ 
    Drug product
• Prolyl hydroxylase inhibitors
  Patent 8,324,208
  Issued: December 4, 2012
  Inventor(s): Duffy Kevin J. & Fitch Duke M. & Jin Jian & Liu Ronggang & Shaw Antony N. & Wiggall Kenneth
  Assignee(s): GlaxoSmithKline LLC
  

  The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

  Patent expiration dates:

  • December 11, 2028
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Prolyl hydroxylase inhibitors
  Patent 8,557,834
  Issued: October 15, 2013
  Inventor(s): Fitch Duke M. & Shaw Antony N. & Wiggall Kenneth
  Assignee(s): GlaxoSmithKline LLC
  

  The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

  Patent expiration dates:

  • June 22, 2027
    
    ✓ 
    Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
• Prolyl hydroxylase inhibitors
  Patent 8,815,884
  Issued: August 26, 2014
  Inventor(s): Fitch Duke M. & Shaw Antony N. & Wiggall Kenneth
  Assignee(s): GlaxoSmithKline LLC
  

  The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I)

  Patent expiration dates:

  • June 22, 2027
    
    ✓ 
    Patent use: TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • February 1, 2028 - NEW CHEMICAL ENTITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer